Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GX-19

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            GX-19 is a potential COVID-19 vaccine developed based on Genexine’s DNA vaccine know-how. The consortium will apply for clinical testing of GX-19 within May, and is expecting to begin testing the vaccine on patients starting early June.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DW2008

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            In vitro antiviral experiments performed against COVID-19 demonstrated that DW2008 had 1.7, 3.8, and 4.7 times higher antiviral activity compared to chloroquine, remdesivir, and Kaletra respectively.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VIR-7831

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vir Biotechnology

            Deal Size: $362.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement April 09, 2020

            Details:

            Through this deal parties are trying to scale up manufacturing of Vir's monoclonal antibody program as a potential treatment for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tertomotide

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            GV1001 has been proven to relieve the aforementioned conditions, as well as help boost immune system, in the preclinical trial phase.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): iCP-NI

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 27, 2020

            Details:

            The new drug iCP-NI begins to verify the efficacy of treatment for the treatment of acute pneumonia and severe sepsis caused by corona19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Heptameric peptide FPR2

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: AD Korea

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 06, 2020

            Details:

            The two companies will promote joint research and development to develop new drugs for the treatment of severe diseases of viral respiratory diseases, such as corona19, using the candidate NCP112.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Immunogenic recombinant vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 06, 2020

            Details:

            G+FLAS has constructed an immunogenic recombinant vaccine candidate expressed in transgenic plants based on its own plant-based protein production platform.